Nectar Lifesciences is a research-driven manufacturer specializing in anti-infectives like cephalosporins and serves as a contract manufacturing organization (CMO) for global pharma innovators. The company operates large-scale manufacturing facilities near Chandigarh with approvals from multiple global regulatory bodies.
Cyborg Score Rationale
The company has delivered poor sales growth of -6.77% over the past five years. Market cap has decreased by -70.34% in one year. The company has low interest coverage ratio and poor return on equity of -5.50% over the last 3 years.
Top Insights
Significant share price deterioration with stock down 61% over the past year (trading at ₹13.49 as of Feb 2026)
Market capitalization halved year-over-year, now at ₹2.61 billion, reflecting investor concerns
Q3 FY25 showed positive momentum with 400% YoY profit increase, though historical trend remains negative
Strong regulatory approvals from EUGMP, PMDA Japan, ANVISA Brazil position company for international growth potential
Named Competitors
Cephalosporin APIs — Large-scale cephalosporin and API manufacturer
Cephalosporin APIs — Diversified API and formulations producer
Cephalosporin APIs — Integrated pharma company with strong API portfolio
Recent Developments
(Dec 2024) Strong Q3 FY25 financial performance with 400% YoY profit increase and improved margins
(Feb 2026) Market capitalization at ₹2.61 billion, down 70% year-over-year
(2025) Promoter holding increased by 6.94% over last quarter, signaling potential confidence restoration
Open the full interactive Nectar Lifesciences Limited report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.